The Quigley Corporation (Nasdaq: QGLY) reported today that intranasal application by spray of Quigley Pharma’s QR-435 demonstrated efficacy in significantly reducing the severity of illness in ferrets infected with the Influenza A virus. Combined with previous QR-435 animal model studies, there is now additional pre-clinical data suggesting that QR-435 can both prevent and treat Influenza A virus in a ferret animal model.
